Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange.
Oxford BioMedica's products use genes as the mediators of a therapeutic effect and/or immune response. The Company has a platform of gene delivery technologies, which are predominately based on highly engineered viral systems. Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how.
11/05/12
Interim Management Statement08/05/12
Presentation of Ocular Clinical Data at ARVO27/04/12
2011 Annual Report and Accounts & AGM Notification17/04/12
Annual Information Update16/04/12
Successful Completion of Phase I/II Study22/03/12
TR-1 Notification of Major Interest in Shares12/03/12
SIGNIFICANT SHAREHOLDING08/03/12
Director / PDMR dealings06/03/12
Preliminary Results24/02/12
Notice of Results
08/02/07
17/04/12
Oxford BioMedica a sell after share price doubles says analyst16/11/11
Oxford BioMedica: five clinical programmes “underway” by 201218/10/11
Oxford BioMedica gets FDA approval for Phase I/IIa trials of deaf/blindness drug23/05/11
Oxford BioMedica’s ProSavin achieves best results to date18/06/10
Oxford Biomedica signs amendment to antigen licence agreement18/06/10
Oxford Biomedica signs amendment to antigen licence agreement with Cancer Research Tech14/06/10
Oxford BioMedica ProSavin treatment of Parkinson's provides continued benefits after 2 years22/01/10
Oxford BioMedica secures intellectual property for ocular products RetinoStat and Encorstat20/01/10
Oxford BioMedica’s gene therapy for Usher syndrome wins orphan drug status from EU agency15/12/09
Oxford BioMedica Receives Orphan Designation for Gene Therapy Treatment for Stargardt Disease
Copyright © Proactiveinvestors.co.uk, 2012. All Rights Reserved Design & Development: Tehnicom Computers
